Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback